Section Arrow
CRDF.NASDAQ
- Cardiff Oncology
Quotes are at least 15-min delayed:2025/07/21 06:59 EDT
Pre Market
Last
 4.38
+0.1 (+2.34%)
Bid
4.28
Ask
4.4
High 4.41 
Low 4.28 
Volume 919 
Regular Hours
Last
 4.28
-0.17 (-3.82%)
Day High 
4.555 
Prev. Close
4.45 
1-M High
4.55 
Volume 
1.59M 
Bid
4.28
Ask
4.4
Day Low
4.27 
Open
4.51 
1-M Low
2.96 
Market Cap 
296.04M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 4.07 
20-SMA 3.64 
50-SMA 3.4 
52-W High 5.6395 
52-W Low 2.01 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.93/-0.93
Enterprise Value
296.85M
Balance Sheet
Book Value Per Share
1.07
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
683.00K
Operating Revenue Per Share
0.01
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TELOTelomir Pharmaceuticals2.28+1.07+88.43%-- 
Pre Market 1.98 -0.3 -13.16%
SRPTSarepta Therapeutics14.075-7.895-35.94%15.76PE
Pre Market 13.01 -1.065 -7.57%
NCNANuCana plc0.0477+0.0009+1.92%-- 
Pre Market 0.0473 -0.0004 -0.84%
RXRXRecursion Pharmaceuticals5.84+0.32+5.80%-- 
Pre Market 6.22 +0.38 +6.51%
MEIPMEI Pharma5.92+1.42+31.56%1.09PE
Pre Market 6.17 +0.25 +4.22%
Quotes are at least 15-min delayed:2025/07/21 06:59 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.